Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Open-label Dose-escalation Study to Evaluate the Safety of Intramuscular Injections of PLX-R18 in Subjects With Incomplete Hematopoietic Recovery Following Hematopoietic Cell Transplantation

NCT03002519 is registered in ClinicalTrials.gov with Pluristem Ltd. as lead sponsor.

NCT NCT03002519
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03002519 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Open-label Dose-escalation Study to Evaluate the Safety of Intramuscular Injections of PLX-R18 in Subjects With Incomplete Hematopoietic Recovery Following Hematopoietic Cell Transplantation
Lead sponsor
Pluristem Ltd.
Phase
Phase 1
Overall status
Completed
Start date
February 8, 2017
Completion date
October 30, 2021
Enrollment
21 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

incomplete hct (hematopoietic cell transplantation)